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Abstract
Background: Reactive microglia have been associated with the histological changes that occur in Parkinson’s disease
brains and mouse models of the disease. Multiple studies from autopsy brains have verified the presence of microgliosis
in several brain regions including substantia nigra, striatum, hippocampus and various cortical areas. MPTP injections in
rodents have also shown striato-nigral microgliosis correlating with the loss of dopaminergic neurons. However,
consistent data with respect to cytokine and immune cell changes during Parkinson’s disease have not been fully defined.
Results: In order to improve understanding of the role of neuroinflammation in Parkinson’s disease, we employed the
MPTP injection model using humanized CD34+ mice along with age-matched C57BL/6 mice. NSG mice engrafted with
hu-CD34+ hematopoietic stem cells were injected with MPTP to quantify cytokine changes, neuron loss, gliosis, and
behavioral dysfunction. The mice were also treated with or without the calcineurin/NFAT inhibitor, FK506, to determine
whether modulating the immune response could attenuate disease. MPTP injections produced impairment of motor
performance, increased microgliosis, elevated brain cytokine levels, and reduced tyrosine hydroxylase
immunoreactivity in the substantia nigra and striatum of both humanized CD34+ mice and C57BL/6 mice
with a strikingly different profile of human versus mouse cytokine elevations observed in each. Interestingly,
FK506 injections significantly attenuated the MPTP-induced effects in the humanized CD34+ mice compared
the C57BL/6 mice. In addition, analyses of human plasma from Parkinson’s disease donors compared to age-matched,
healthy controls demonstrated an increase in a number of pro-inflammatory cytokines in female patients similar to that
observed in MPTP-injected female CD34+ mice.
Conclusions: This study demonstrates for the first time, induction of Parkinson’s disease-like symptoms in female
humanized CD34+ mice using MPTP. The profile of cytokine changes in the serum and brains of the humanized CD34
+ mice following MPTP injection differed significantly from that occurring in the more commonly used C57BL/6 strain
of mice. Moreover, several cytokine elevations observed in the MPTP injected humanized CD34+ mice were similarly
increased in plasma of PD patients suggesting that these mice offer the more relevant model for the inflammatory
aspects of human disease. Consistent with this, the effects of MPTP on loss of tyrosine hydroxylase immunoreactivity,
loss of motor strength, and increase in proinflammatory cytokines were attenuated using an immunosuppressant drug,
FK506, in the humanized CD34+ but not the C57BL/6 mice. Collectively, these findings suggest that MPTP injected,
humanized CD34+ mice represent a more accurate model for assessing inflammatory changes in PD.
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Background
Immunoreactive microglia have been reported in both
human brains and animal models of Parkinson’s disease
[1–7]. Multiple studies of autopsy brains have shown
microgliosis in not just the substantia nigra but also the
striatum, hippocampus and other cortical areas [5–13].
Reports using rodent models of disease also demonstrate
increased microgliosis correlating with dopaminergic
neuron loss using the rat 6-hydroxydopamine (6-OHDA)
toxin injection model [3]. The LPS-injected rodent
model of Parkinson’s disease (PD) also produces micro-
gliosis [2]. Similarly, MPTP injection into rodents also
results in striato-nigral microgliosis correlating with loss
of dopaminergic cells [4]. Nevertheless, it is not yet clear
whether the reactive microglia are a cause or effect of
neuron loss during disease progression. Collectively,
histologic findings from human brains and temporal
analysis from rodent studies continue to support the
idea that microglia activation and the associated inflam-
matory changes are part of the disease process.
In addition to the brain pathology, numerous studies re-
port altered peripheral immune cell responses during dis-
ease suggesting a possible communication between the
peripheral immune system and the central nervous system
[14, 15]. A number of clinical studies have suggested that
select inflammatory markers in the blood of PD patients
may correlate with the degree of severity of the disease or
disease-associated symptoms such as depression, anxiety,
fatigue and sleep patterns changes [16–23].
In spite of the studies of human autopsy brains, clin-
ical reports involving PD patients, and rodent models of
the disease all having correlative findings, a number of
conflicting reports exist. For example, animal models for
PD have not been able to fully define the temporal
changes of inflammatory response with respect to dis-
ease progression and neuron loss. Ideally, the rodent
models of disease should accurately reflect the human
condition to allow for mechanistic dissection. This is
demonstrated concretely by the fact that only after
characterization of human TNF-α overexpressing mice
was TNF-α fully realized as a valid arthritis target [24].
In order to determine the contribution of neuroinflam-
matory changes to the neuron loss and motor dysfunc-
tion associated with PD, we employed a mouse
humanized CD34+ line designed to contain engrafted
multi-lineage human immune cell populations following
injection of CD34+ hematopoietic stem cells [25]. The
humanized CD34+ mice, along with age-matched
C57BL/6 mice, were injected with MPTP to produce
PD-like symptoms with or without intravenous injection
of the immunosuppressive calcineurin/NFAT inhibitor
drug, FK506, as a neuroprotectant. As expected, MPTP
injections resulted in loss of dopaminergic neuron tyro-
sine hydroxylase (TH) immunoreactivity, decreased
motor strength as seen from pole tests and grip strength
tests, and increased microgliosis/astrogliosis. Interest-
ingly, FK506 was able to attenuate the behavioral prob-
lems, cytokine levels, TH loss, and microgliosis/
astrogliosis only in the humanized CD34+ mice. The
mouse compared to human serum and brain cytokine
profiles were also different across the two strains of
mice. This study demonstrates for the first time that
MPTP induces PD-like symptoms in female humanized
CD34+ compared to female C57BL/6 mice. We also re-
port a valid therapeutic target, calcineurin/NFAT activity,
for treating motor impairment and inflammation in the
humanized immune system model by using a clinically
available drug, FK506. Finally, we validated that several
of the peripheral cytokine changes observed in the
MPTP-injected humanized CD34+ mice but not the
C57BL/6 mice paralleled changes observed in human
PD plasma suggesting that these mice may be a more
accurate model for understanding human disease.
Methods
Animals
The humanized NOD scid gamma (NSG) mice and age-
matched wild type mouse line, C57BL/6, were purchased
from the Jackson Laboratory (Bar Harbor, Maine). For
generation of humanized NSG mice, female NSG mice
are injected with human hematopoietic stem cells
(hCD34+) [25, 26]. Engraftment of mature human white
blood cells (hCD45+) is confirmed 12 weeks after the in-
jection [27]. Mice with more than 25% hCD45+ cells
were considered successfully humanized and housed in a
BSL2 negative pressure facility before shipping to UND.
The mice obtained for this study were engrafted with
hematopoietic stems cells from one individual with total
hCD45+ cells engraftment ranging from 56 to 71%. The
mice were 16 weeks of age at the time of arrival and
allowed to acclimate for 7 days before experimentation.
The mice were randomly divided into 4 groups: saline
injection, MPTP injection, FK506 injection or MPTP
and FK506 injection.
Animal use
All animal use was approved by the University of North
Dakota Institutional Animal Care and Use Committee
(UND IACUC). Mice were provided food and water ad
libitum and housed in a 12 h light/dark cycle. The inves-
tigation conforms to the National Research Council of
the National Academies Guide for the Care and Use of
Laboratory Animals (8th edition).
Antibodies and reagents
Anti-TH antibody was purchased from EMD Millipore
(Billerica, MA). Anti-Iba-1 antibody and anti-GFAP anti-
body were from Wako Chemicals (Richmond, VA) and
Manocha et al. Molecular Neurodegeneration  (2017) 12:17 Page 2 of 18
Cell Signaling Technology, Inc. (Danvers, MA), respect-
ively. The horseradish peroxidase conjugated secondary
antibodies were purchased from Santa Cruz Biotechnol-
ogy (Santa Cruz, CA). Mouse TNF-α ELISA kit was
obtained from R&D Systems (Minneapolis, MN). Elite
Vectastain ABC avidin and biotin kits, biotinylated anti-
rabbit, anti-mouse, and anti-rat antibodies and the
Vector VIP kits were from Vector Laboratories Inc.
(Burlingame, CA). The anti-CD68 antibody was obtained
from AbD Serotec (Raleigh, NC). Human specific anti-
CD68 and anti-HLA-DR (LN3) antibodies were from
Bio-Rad (Hercules, CA). The human specific anti-CD45
antibody was purchased from Dako (Carpinteria, CA).
MPTP and FK506 treatments
The 16-week old female CD34+ mice and the age-
matched C57BL/6 mice were given 3 intraperitoneal
(i.p.) injections of saline vehicle or MPTP-HCl (18 mg/kg
of free base) at 2 h intervals for a total of 3 injections. For
FK506 treatments, mice were given saline vehicle or
10.0 mg/kg/day starting 30 min after the first MPTP
injection and continuing through 4 additional days after
the last MPTP injection, totaling 5 days of FK506
injections.
Pole test
Following the MPTP and FK506 injections, mice were
housed for an additional 3 days and behaviorally tested
on day 8. Each animal was administered the pole test to
assess locomotor activity as a measure of dopaminergic
neuron function following the MPTP injections [28].
Briefly, mice were placed head-upward on the top of a
vertical rough-surfaced pole (diameter 8 mm, height
55 cm) with a base that was positioned on a flat surface.
The time until the mouse descended to the bottom of
the pole/cage floor (locomotor activity time, TLA) was
recorded with a maximum of 120 s. Mice were returned
to their home cages after testing and the pole was wiped
clean with 50% ethanol in between mice and allowed to
dry before the next trial.
Grip strength test via Kondziela’s inverted screen test
To test gross strength of the four limb muscles in mice,
mice were challenged with the inverted screen test as
previously described by Deacon et al [29]. A 43 x
43 cm2 square wire mesh frame was made for this pur-
pose. The mesh was12 x 12 mm2 square formed by 1-
mm diameter wires. The frame was 4 cm deep wooden
beading to prevent mice from climbing to the other side
of the mesh. After a 15 min rest following the pole test,
each mouse was placed onto the center of the mesh
square frame and the screen was rotated over the course
of 2 s to an inverted position with the mouse head de-
clining first. The screen was held at 40-50 cm over a
clean surface, and the time it took each mouse to let go
of the screen was measured until the maximum of 120 s
was reached. After testing, mice were returned to their
home cages.
Tissue and serum collection
Following the behavioral tests, the mice were euthanized
by i.p. injection of a mixture of 100 mg/kg ketamine/
16 mg/kg xylazine, followed by cardiac exsanguination
and PBS perfusion. Blood was collected and serum sepa-
rated by centrifugation at 2000 x g for 10 min at 4 °C for
ELISA arrays. The brain, spleen and intestines were col-
lected from each mouse. The striatum was dissected out
of the right cerebral hemisphere and flash frozen in
liquid nitrogen. A portion of the ileum and spleen were
also flash frozen. The left cerebral hemisphere and
remaining spleen and ileum samples were immersion-
fixed using 4% paraformaldehyde in PBS. The fixed
tissue was cryoprotected through 2 successive 30%
sucrose changes before sectioning.
Human plasma and tissue
Age matched human plasma (Parkinson’s disease and
healthy controls) were obtained from the Harvard
Biomarkers Study (http://neurodiscovery.harvard.edu/
biomarkers-core). Human normal adult spleen frozen
sections were purchased from BioChain Institute, Inc.
(Newark, CA). Slides were first processed for antigen
retrieval by boiling in Tris-EDTA, pH 9.0, for 20 min,
then immunostained along with mouse spleen and intes-
tine sections as described below.
Immunostaining mouse brains
The left cerebral hemispheres for humanized CD34+
and age-matched C57BL/6 mice (saline, FK506, MPTP
and MPTP + FK506) were sectioned using a freezing
microtome. Briefly, multiple paraformaldehyde-fixed and
sucrose-equilibrated tissues were embedded in a 15%
gelatin (in 0.1 M phosphate buffer, pH 7.4) matrix to
form a sample block for simultaneous processing. The
block was immersed in a 4% paraformaldehyde solution
for 3-4 days to harden the gelatin matrix, followed by re-
placing the solution with 30% sucrose every 3-4 days
each for 2 weeks. The blocks were then flash frozen
using dry-ice/isomethylpentane, and 40 μm serial
sections were cut using a freezing microtome. Serial
sections (960 μm apart) were immunostained using anti-
TH antibody (1:1000 dilution), anti-Iba-1 antibody
(1:500 dilution) or anti-GFAP antibody (1:1000 dilution).
The antigens were visualized using Vector ABC kit and
Vector VIP as the chromogen (Vector Laboratories, Inc.,
Burlingame, CA) according to the manufacturer proto-
cols. The slides were coverslipped using VectaMount
(Vector Laboratories) following a standard dehydrating
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procedure through a series of ethanol concentrations
and Histo-Clear (National Diagnostics, Atlanta, GA).
Photomicrographs were taken using an upright Leica
DM1000 microscope and Leica DF320 digital camera
system. Quantitation of immunostaining was performed
as previously described [30]. Briefly, optical densities
from the striatum, substantia nigra, and hippocampus
regions from the same serial sections were measured
using Adobe Photoshop software (Adobe Systems, San
Jose, CA). The values for each section were averaged (4
sections/brain, 4-5 brains per condition) and compared.
Immunostaining peripheral tissue
Spleen and ileum samples were serially cut (10 μm) onto
gelatin subbed slides using a cryostat. These sections,
along with human spleen slides (positive controls), were
immunostained using anti-CD68 (1:500), anti-hCD68
(1:500), anti-HLA-DR (LN3) (1:500) and anti-hCD45
(1:250) antibodies. The immunostaining was visualized
using Vector VIP as the chromogen.
ELISA arrays
Striatal samples and serum from all groups of human-
ized CD34+ and C57BL/6 mice were flash frozen follow-
ing collection. Pre-weighed samples from mice and
human plasma samples were used for multi-analyte
ELISA arrays (Qiagen, Valencia, CA) and the levels of
various cytokines were determined as per the manufac-
turer protocol. Human and mouse Inflammatory Cyto-
kines Multi-Analyte ELISArray kits from Qiagen were
chosen in order to obtain expression of a wide array of
inflammatory and anti-inflammatory cytokines. Cytokine
concentrations were normalized by tissue weight.
Design-based stereological quantification of Iba-1 positive
cells
Paraformaldehyde-imbedded sections from humanized
CD34+ and age-matched C57BL/6 mice (saline, FK506,
MPTP and MPTP + FK506) were cut at 40 μm intervals
and immunolabled for Tyrosine Hydroxylase (TH), Iba-1
and GFAP. Sections from three different mice for each
condition of mice were assessed for TH, GFAP or Iba-1-
positive nuclei with the section interval set at 960 μm.
Non-biased quantification of immuno-positive nuclei was
conducted using the optical fractionator method originally
developed by West and colleagues [31] and adapted from
previous studies with other neural populations [32, 33].
TH, GFAP or Iba-1-positive cells in the temporal cortex
layer were counted in every 24th section using StereoIn-
vestigator 11.06.2 (Microbrightfield Inc., Williston, VT) on
an Olympus BX51WI equipped with a motorized x, y, and
z stage. In each animal, immuno-positive cells were
counted from 21 to 30 randomly and systematically se-
lected frames in every serial section using the 40x
objective. For cell counting, the contour of the Substantia
Nigra was delineated with 2× magnification based on
standard anatomical markers and the grid size set follow-
ing sub-sampling optimization. In brief, the number and
location of counting frames and the counting depth for
that section were determined by entering parameters for
the grid size (300 X 300 μm), the thickness of top guard
zone (2 μm) and the optical dissector height (26 μm). The
guard zones were set at 2 μm above and below the count-
ing depth for each section with regional thickness and
variation in section integrity taken into consideration and
the max and min z-depth determined at each sampling lo-
cation prior to counting. The optimal counting frame
width (100 μm) and height (100 μm) were determined
with an initial oversampling of a representative set of sec-
tions from control and treated samples. The cell bodies of
the TH, GFAP or Iba-1-positive cells were counted if they
were entirely within the 26 μm depth of the counting frame
and only at the z-depth at which the nucleus was in focus.
The StereoInvestigator software calculated the total num-
ber of Iba-1, TH, and GFAP-positive cells in the temporal
cortex using the 3D optical fractionator formula designated:
N= t/h X 1/ssf X 1/asf X 1/hsf X ΣQ-. For the calculations,
“t/h” is the section mounted thickness over the counting
frame height; “ssf” is the section sampling fraction; “asf” is
the area sampling fraction, which was calculated by dividing
the area sampled with total area of the temporal cortex (in
our tracings, the sum of temporal cortex areas sampled in
every 24th section); “hsf” is the height sampling fraction,
which was determined by dividing the height of the count-
ing frame (26 μm) by the section thickness determined for
each sampling site (37-39 μm on average); and “ΣQ”- de-
notes the total count of particles sampled for the entire
temporal cortex. The sampling was optimized for maximal
efficiency, with a final mean coefficient of error (CE, Gun-
dersen) of less than 10% for all sections sampled. One-way
analysis of variance (ANOVA; GraphPad Prism, 6.0c;
LaJolla, CA) was used to analyze positive nuclei and all data
are presented as mean ± SD for n = 3 samples.
Statistical analysis
Data are presented as mean ± standard deviation. Values
statistically different from controls were determined
using one-way ANOVA (or two-way ANOVA where
required). The Turkey-Kramer multiple comparisons
post-test was used to determine p values.
Statistical analysis for human plasma cytokine ELISA
arrays
A total of 140 plasma samples were analyzed to deter-
mine cytokine level differences in 4 groups: female Par-
kinson’s disease donors, female healthy controls, male
Parkinson’s disease donors and male healthy controls.
Initial sample size for all 4 conditions was n = 35.
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Following ELISA experiments for 12 cytokines, the sam-
ples that were below the detection limit were excluded
from the analyses. The samples that did not represent
the population for a 95% confidence interval i.e. the
values that were 2 times standard deviations above or
below the mean were also excluded from the analyses.
This resulted in a sample size ranging from 14 to 34 for
all the cytokines but IL-4 (n = 5-7). Values statistically
different between the groups were determined using
two-way ANOVA with Holm-Sidak post-hoc test.
Results
MPTP injected C57BL/6 and humanized CD34+ mice
showed reduced motor strength based on the grip
strength and pole tests
Following MPTP and/or FK506 injections, the motor
function of mice was assessed using the grip strength
and pole tests. As expected, the MPTP injection groups
of both humanized CD34+ and C57BL/6 mice showed
deteriorated performance in both tests (Fig. 1). Interest-
ingly, FK506 significantly improved both pole test and
grip strength performance of the MPTP injected human-
ized CD34+ mice (Fig. 1, b & d). However, FK506 treat-
ment of MPTP-injected C57BL/6 mice failed to improve
performance in either of the tests (Fig. 1, a & c). The dif-
ference between general time values for the CD34+ and
C57BL/6 strains in grip strength can be attributed to our
observations that C57BL/6 mice were unable to hold
onto the test surface (inverted mesh frame) for very long
irrespective of the treatment group they belonged to.
Humanized CD34+ mice, in general, held onto the mesh
surface much longer, hence their time values on the y-
axis are quite different even in the saline-injected mice
compared to C57BL/6 mice.
FK506 attenuated MPTP-mediated decrease in TH immu-
noreactivity in the striatum and substantia nigra of hu-
manized CD34+ mice but not C57BL/6 mice
To assess the effect of MPTP on dopaminergic neurons,
brain sections from all groups of animals were immuno-
stained using anti-TH antibody as the dopaminergic cell
marker to quantify changes via both densitometric and
stereologic evaluation. Tyrosine hydroxylase (TH) is the
rate limiting enzyme in the synthesis of dopamine.
Therefore, it is a reliable marker for neuronal dopamine
synthesis. As expected, MPTP injections reduced TH
immunoreactivity in both the substantia nigra and stri-
atum of the humanized CD34+ mice (Fig. 2a, “MPTP”).
In contrast, FK506 treatment significantly attenuated the
MPTP-mediated reduction in TH immunoreactivity
(Fig. 2a, MPTP + FK506). Quantitation of the immuno-
reactivity indicated that the MPTP/FK506 group had
Fig. 1 MPTP injected C57BL/6 and humanized CD34+ mice showed reduced motor strength based on the grip strength and pole tests. The
hCD34+ mice and age-matched C57BL/6 female mice were intraperitoneal injected three times with saline vehicle or MPTP-HCL (18 mg/kg) at
2 h intervals followed by FK506 injections (10 mg/kg/day) for 5 days. Mice were tested for grip strength (a, b) and pole test (c, d) 7 days post
MPTP injections. Results were averaged from 8 to 10 mice (CD34+) and 4-10 (C57BL/6) per group and plotted ± SD (*p < 0.05)
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approximately 2-fold more TH immunoreactivity in the
striatum and a similar increase in TH positive cell num-
bers in the substantia nigra when compared to the
MPTP only group (Fig. 2, b &c). To compare the effects
of FK506 in C57BL/6 mice, TH immunoreactivity was
again quantified from striatum and substantia nigra
using densitometric and stereologic evaluation. MPTP-
injected mice had decreased TH immunoreactivity in
both regions as was observed with the humanized CD34
+ mice (Fig. 3). However, unlike humanized CD34+
mice, FK506 treatment did not significantly affect the
MPTP-dependent decrease in TH immunoreactivity in
the C57BL/6 mice in either region (Fig. 3, b &c). How-
ever, it should be noted that only 4 out of 10 treated ani-
mals survived from the MPTP + FK506 treatment
suggesting that the combination of drugs was more toxic
to the C57BL/6 females.
MPTP injections increased microgliosis in the striatum,
substantia nigra, and hippocampus of humanized CD34+
mice
To examine microglial activation following MPTP injec-
tions, brain sections from MPTP- and FK506-injected
humanized CD34+ mice were immunostained for a
microglia marker, Iba-1. The staining intensity and the
morphology of the stained cells were then analyzed to
determine the activation status of microglia. The mice
injected with MPTP showed increased microgliosis in
the striatum, substantia nigra and hippocampus as
compared to saline- and FK506-injected mice, while
concomitant FK506 injections visibly attenuated the
MPTP-induced microgliosis (Fig. 4a). Densitometric
quantitation of Iba-1 immunoreactivity from the stri-
atum and hippocampus and stereological quantitation of
Iba-1 positive cells from substantia nigra indicated that
FK506 treatment significantly decreased MPTP-induced
microgliosis (Fig. 4, b-d). This demonstrated that the
behavioral improvements and neuroprotection provided
by FK506 in these mice correlated with decreased micro-
glial activation.
MPTP injections increased microgliosis in the striatum,
substantia nigra, and hippocampus of C57BL/6 mice
For comparison purposes, microgliosis in MPTP-
injected C57BL/6 mice was also quantified. The C57BL/
6 mice injected with MPTP showed significantly higher
Iba-1 immunoreactivity in the striatum, substantia nigra,
and hippocampus as was observed in the humanized
CD34+ mice. FK506 treatment also reduced the MPTP-
induced microgliosis in the striatum and hippocampus
(Fig. 5, a&b). However, unlike the humanized CD34+
mice, the effect of FK506 in the substantia nigra was not
Fig. 2 FK506 attenuated the decrease of TH immunoreactivity in the striatum and substantia nigra of MPTP injected humanized CD34+ mice. The
hCD34+ mice female mice were intraperitoneal injected three times with saline vehicle or MPTP-HCL (18 mg/kg) at 2 h intervals followed by
FK506 injections (10 mg/kg/day) for 5 days. Eight days post MPTP injections, brains were dissected out and right hemispheres fixed and immunostained
using anti-TH antibody. a Representative images from striatum and substantia nigra are shown at 1× magnification. b Optical density of immunopositive
staining from striatum and c number of TH-positive cells from substantia nigra were measured and averaged 4-5 sections per brain and 4–5 animals per
group ± SD (*p < 0.05)
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significant in C57BL/6 mice (Fig. 5c). This demonstrated
that in spite of no behavioral recovery or neuroprotec-
tion in these mice, the drug had some modest effect on
microglial activation.
MPTP injections increased astrogliosis in the substantia
nigra and hippocampus of humanized CD34+ mice
MPTP has been shown to also induce astrocyte acti-
vation in mice [34]. In order to examine astroglial
activation in the MPTP-injected humanized CD34+
mice, brain sections were immunostained for glia
fibrillary acidic protein (GFAP), an astrocyte-specific
marker. MPTP induced marked astrocyte activation
both in the substantia nigra and hippocampus (Fig. 6)
while no GFAP immunostaining was observed in the
striatum of these mice (data not shown). Similar to
microgliosis, MPTP-induced astrogliosis was sup-
pressed by FK506 in both regions (Fig. 6a). Densito-
metric analysis showed that MPTP increased GFAP
immunoreactivity by approximately 2-fold in the
hippocampus while the number of GFAP positive cells
in the substantia nigra showed a 4-fold increase with
MPTP, and FK506 significantly and almost entirely re-
duced the MPTP-mediated increase in GFAP immu-
noreactivity (Fig. 6, b & c).
MPTP injections increased astrogliosis in the substantia
nigra of C57BL/6 mice
Astrogliosis in the MPTP-injected C57BL/6 mice was
also quantified in parallel with the humanized CD34+
mice. The MPTP-injected mice showed a significantly
higher level of GFAP immunoreactivity in the hippo-
campus as was observed in the humanized CD34+
mice (Fig. 7a). However, FK506 treatment reduced the
hippocampal MPTP-mediated astrogliosis only mar-
ginally (Fig. 7b). Furthermore, MPTP injections re-
sulted in a significant increase in GFAP stained cells
in the substantia nigra in C57BL/6 mice (Fig. 7c).
Similarly, the effect of FK506 on inhibition of sub-
stantia nigra astrogliosis in the MPTP-injected
C57BL/6 mice was not statistically significant. There
were no GFAP immuno-positive cells in the striatum
of these mice as in the humanized CD34+ mice (data
not shown).
Human HLA-DR and CD45 immunoreactivity was observed
in the spleen, intestine and brain of the humanized CD34+
mice
To determine whether human macrophages in the
humanized CD34+ mice contributed to the changes
observed in the spleen, intestine, and brain by infiltrating
into these regions, macrophage proteins, CD68, CD45
Fig. 3 FK506 provided no protection of TH immunoreactivity in the striatum and substantia nigra of MPTP injected C57BL/6 mice. C57BL/6
female mice were intraperitoneal injected three times with saline vehicle or MPTP-HCL (18 mg/kg) at 2 h intervals followed by FK506 injections
(10 mg/kg/day) for 5 days. Eight days post MPTP injections, brains were dissected out and right hemispheres fixed and immunostained using
anti-TH antibody. a Representative images from striatum and substantia nigra are shown at 1× magnification. b Optical density of immunopositive
staining from striatum and c number of TH-positive cells from substantia nigra were measured and averaged for 4–5 sections per brain from 4 to 5
animals per group ± SD (*p < 0.05)
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and HLA-DR (LN3) were immunodetected using
human-specific antibodies. Mouse-specific CD68 anti-
body was also used to differentiate macrophages/micro-
glia of mouse origin. Sparse, but clearly detectable
immunoreactivity for human HLA-DR and CD45 were
found in the intestines of the CD34+ mice (Fig. 8). Fur-
thermore, the spleens from these animals also showed
robust immunoreactivity for human CD68 in addition to
HLA-DR and CD45. However, the brain sections from
these mice exhibited only minimal immunoreactivity for
the human antigens. Human HLA-DR and human CD45
immunoreactivity was occasionally observed in the men-
ingeal layers (Fig. 8), suggesting that human macro-
phages have limited infiltration into the brain. There was
no CD68 immunoreactivity observed in the brain con-
sistent with the lack of CD68 immunostaining in the
intestines (Fig. 8). To test the specificity of the human-
specific antibodies, spleens and intestines from C57BL/6
mice were immunostained as negative controls. As ex-
pected, the human-specific antibodies showed no immu-
noreactivity for CD68, CD45 and HLA-DR in these
mice, which produced only mouse antigens. As a
Fig. 4 MPTP injections increased microgliosis in the striatum, substantia nigra, and hippocampus of humanized CD34+ mice. The hCD34+ mice
were intraperitoneal injected three times with saline vehicle or MPTP-HCL (18 mg/kg) at 2 h intervals followed by FK506 injections (10 mg/kg/
day) for 5 days. Eight days post MPTP injections, brains were dissected out and right hemispheres fixed and immunostained using anti-Iba-1
antibody (microglia marker). a Representative images from striatum, substantia nigra and hippocampus are shown at 10× magnification with
63× magnification insert. Optical density of immunopositive staining from b striatum and d hippocampus were measured from 3 to 4 optical fields at
10× magnification per section from 4 to 5 animals per group and c number of Iba-1 positive cells from the substantia nigra were counted and
averaged ± SD (*p < 0.05)
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positive control, human spleen sections were immuno-
stained using the human-specific CD68, CD45 and
HLA-DR antibodies (Fig. 8, right column). All of these
antibodies showed positive immunoreactivity in these
sections, indicating their specificity to the human
macrophage marker proteins.
FK506 downregulated the MPTP-induced increase of
serum inflammatory cytokine levels in the humanized
CD34+ mice
Based on the findings that MPTP induced microgliosis
in the brain and subsequent FK506 treatment reduced it
in the humanized CD34+ mice, it was likely that
inflammatory cytokine levels were elevated by MPTP
and downregulated by FK505. Since few human cells
were detected in the brains of CD34+ mice, we hypothe-
sized that MPTP-induced microgliosis in the brain oc-
curred primarily via cross-talk between peripheral
cytokines and brain microglia. However, since HLA-DR
immunoreactivity was observed in the brain tissue,
though sparse, we cannot rule out the possibility of par-
enchymal cytokine production in the brains of these
mice. In order to test the idea of periphery to brain com-
munication, we next determined the serum inflamma-
tory cytokine profile in these mice using human-specific
multi-analyte ELISA arrays. MPTP-injected humanized
Fig. 5 MPTP injections increased microgliosis in the striatum, substantia nigra, and hippocampus of C57BL/6 mice. C57BL/6 female mice were
intraperitoneal injected three times with saline vehicle or MPTP-HCL (18 mg/kg) at 2 h intervals followed by FK506 injections (10 mg/kg/day) for
5 days. Eight days post MPTP injections, brains were dissected out and right hemispheres fixed and immunostained using anti-Iba-1 antibody
(microglia marker). a Representative images from striatum, substantia nigra and hippocampus are shown at 10× magnification with 63× magnification
insert. Optical density of immunopositive staining from b striatum and d hippocampus were measured for 3–4 optical fields at 10× magnification per
section from 4 to 5 animals per group and c number of Iba-1 positive cells from substantia nigra were counted and averaged ± SD (*p < 0.05)
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Fig. 6 MPTP injections increased astrogliosis in the substantia nigra and hippocampus of humanized CD34+ mice. The hCD34+ mice were
intraperitoneal injected three times with saline vehicle or MPTP-HCL (18 mg/kg) at 2 h intervals followed by FK506 injections (10 mg/kg/day) for
5 days. Eight days post MPTP injections, brains were dissected out and right hemispheres fixed and immunostained using anti-GFAP antibody
(astrocyte marker). a Representative images from substantia nigra and hippocampus are shown at 10× magnification. Optical density of immunopositive
staining from the b hippocampus was measured and averaged for 3–4 optical fields at 10× magnification per section from 4–5 animals per group and c
number for GFAP positive cells from the substantia nigra were counted and averaged ± SD (*p < 0.05)
Fig. 7 MPTP injections increased astrogliosis in the hippocampus of C57BL/6 mice. C57BL/6 female mice were intraperitoneal injected three times
with saline vehicle or MPTP-HCL (18 mg/kg) at 2 h intervals followed by FK506 injections (10 mg/kg/day) for 5 days. Eight days post MPTP injections,
brains were dissected out and right hemispheres fixed and immunostained using anti-GFAP antibody (astrocyte marker). a Representative images from
substantia nigra and hippocampus are shown at 10× magnification. Optical densities of immunopositive staining from the b hippocampus
was measured and averaged for 3–4 optical fields at 10× magnification per section from 4 to 5 animals per group and c number for GFAP
positive cells from the substantia nigra were counted and averaged ± SD (*p < 0.05)
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CD34+ mice showed increased levels of IL-1α, IL-1β, IL-2,
IL-4, IL-6, IL-8, IL-10, IL-12 and IL-17A cytokines (Fig. 9).
As anticipated, all of the above cytokines were significantly
downregulated by the concomitant FK506 treatment. The
levels of IFN-γ, TNFα and GM-CSF were not affected by
either MPTP or subsequent FK506 treatment.
Serum of humanized CD34+ and C57BL/6 mice displayed
differential changes in levels of mouse cytokines
We next examined the serum levels of mouse-specific
cytokines in the humanized CD34+ and C57BL/6 mice
for comparison across the strains. Mouse-specific in-
flammatory cytokine ELISA arrays indicated that the
cytokine responses to MPTP administration in human-
ized CD34+ mice were distinct from those of C57BL/6
mice (Fig. 10). MPTP increased the serum levels of
mouse cytokines, IL-2, IL-4, IL-6, IL-10, IL-12, IL-17A,
IFN-γ and GM-CSF, more notably in the CD34+ mice.
MPTP-induced changes in mouse versus human cyto-
kine profiles were also compared in the humanized
CD34+ mice. In contrast to the effect on human cyto-
kine levels, FK506 treatment only attenuated levels of
the mouse cytokines, IL-2, IFN-γ and GM-CSF. Unlike
the humanized mice, MPTP injections in C57BL/6 mice
did not affect mouse cytokine levels in serum (Fig. 10).
MPTP injections increased levels of human inflammatory
cytokines in the striatum of humanized CD34+ mice
Since MPTP injections increased inflammatory cytokine
levels in the serum of humanized CD34+ mice we
examined whether the inflammatory response was trans-
lated to the brain. MPTP injected humanized CD34+
mice had increased levels of human IL-1α, IL-1β, IL-2,
IL-4, IL-6, IL-8, IL-10 and IL-12, IL-17A and TNF-α
compared to saline injected mice (Fig. 11). Based upon
that fact that there were few detectable macrophages in
the brain (Fig. 6), this data suggests that the elevated
levels of human cytokines may be transported in from
the blood. Interestingly, FK506 treatment only signifi-
cantly decreased cytokine levels of IL-4, IL-6, IL-8 and IL-
12 in the striatum following MPTP injections (Fig. 11).
The striatum of humanized CD34+ and C57BL/6 mice
displayed different murine cytokine levels after MPTP or
FK506 injection
As with the serum, we next compared mouse brain cyto-
kine differences across strains and for comparison to
human brain cytokine levels in the humanized CD34+
mice. Overall, as expected, mouse cytokines levels were
significantly lower in striatum of humanized CD34+ as
compared to C57BL/6 mice (Fig. 10). There were no
significant differences in striatal cytokine levels between
saline and MPTP injected humanized CD34+ mice
(Fig. 10). This demonstrated a clear difference between
human and mouse cytokine changes in the brains of the
MPTP injected humanized CD34+ mice. On the other
hand, compared to saline injected animals the MPTP
injected C57BL/6 mice had higher striatal IL-1α, IL-1β,
IFN-γ and TNFα levels (Fig. 12). FK506 treatment had
no effect on the MPTP-induced increase consistent with
Fig. 8 Human HLA-DR and human CD45 immunoreactivities were observed in the spleens, intestines, and occasionally in brain meninges of the
humanized CD34+ mice. Intestines, spleens and brains (right hemispheres) were dissected out from 16 weeks old, female C57BL/6 and hCD34+
MPTP injected mice and fixed using 4% paraformaldehyde. Fixed tissue along with human spleen sections (positive controls) were immunostained
using anti-CD68 (rodent specific), anti-CD68 (human specific), anti-HLA-DR (LN3, human specific), and anti-CD45 (human specific) antibodies. Intestine
and spleen representative images at 10× magnification and brain representative images at 20× magnification are shown
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no behavioral or histologic improvement from drug
treatment in the C57BL/6 female mice.
Human PD plasma had elevated levels of IL-1α, IL-2, IL-4
and IL-6 compared to healthy controls
In order to validate that the inflammatory changes in
CD34+ humanized mice represented the human disease,
human plasma cytokine levels were quantified via ELISA
from Parkinson’s disease donors and healthy controls.
Female patients with Parkinson’s disease (PD) showed el-
evated levels of IL-1α, IL-2 and IL-6 while male patients
with PD showed elevated levels of only IL-4 compared
to healthy controls (Fig. 13). Interestingly, IFN-γ levels
in male patients with PD were significantly lower than in
male controls. Although there were significant differ-
ences in multiple cytokine levels between males and
females (Fig. 13), the increase in some of the inflamma-
tory cytokines in plasma of female patients with PD
compared to age-matched female controls paralleled the
observed increases in serum and brains of the female
MPTP-injected humanized CD34+ mice. This data is
largely consistent with a previously reported study by
Nagatsu et al. demonstrating an increase in various cyto-
kines (TNF-α, IL-1β, IL-2, IL-4 and IL-6 in the striatum
and cerebrospinal fluid of Parkinson’s disease patients
[35].
Discussion
Our findings suggest that female C57BL/6 and female
humanized CD34+ mice can both be used with the
MPTP model of PD. Moreover, we observed profound
strain as well as species differences with respect to
MPTP-induced changes and their response to anti-
inflammatory FK506 treatment. MPTP injection pro-
duced the expected impairment of motor performance,
increased microgliosis, increased astrogliosis, elevated
brain cytokine levels, and reduced TH immunoreactivity
in the substantia nigra and striatum of C57BL/6 mice.
Fig. 9 FK506 attenuated the MPTP-dependent increase of human inflammatory cytokine levels in humanized CD34+ mice serum. The hCD34+
mice were intraperitoneal injected three times with saline vehicle or MPTP-HCL (18 mg/kg) at 2 h intervals followed by FK506 injections (10 mg/
kg/day) for 5 days. Eight days post MPTP injections, serum was collected and used for human specific multi-analyte cytokine ELISA arrays. Cytokine
levels were determined from 6 animals per group ± SD (*p < 0.05)
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However, there were no changes in serum cytokine
levels in the female C57BL/6 mice following MPTP
treatment and FK506 provided no significant protective
effects as assessed by behavior, TH immunoreactivity,
Iba-1 microglial immunoreactivity, or brain and serum
cytokine levels. This suggests, for reasons unclear, that
the drug did not have a robust anti-inflammatory effect
in the C57BL/6 mice. A similar decrease in TH immu-
noreactivity, increased microgliosis, astrogliosis and
impaired motor performance was observed in the MPTP
injected humanized CD34+ mice demonstrating conser-
vation of toxin-mediated neuron death and disease mod-
eling in this line. In addition, these mice had an increase
in select mouse cytokines in the both blood and brains
following MPTP injection quite different from changes
observed in the C57BL/6 mice. More importantly, both
blood and brain levels of specific human cytokines were
elevated in the MPTP injected mice demonstrating a
possibility that the blood cytokine level profile may be
used as a biomarker of brain cytokine levels and neur-
onal loss. This idea is further supported by cytokine
analyses of human PD plasma compared to healthy
controls. Plasma from female PD patients and the
MPTP-injected humanized CD34+ mice showed an
increase in IL-1α, IL-2, and IL-6 compared to controls.
This suggests that these cytokines could be further
Fig. 10 Serum of humanized CD34+ and C57BL/6 mice displayed differential changes in levels of mouse cytokines. Humanized CD34+ and C57BL/6
female mice were intraperitoneal injected three times with saline vehicle or MPTP-HCL (18 mg/kg) at 2 h intervals followed by FK506 injections
(10 mg/kg/day) for 5 days. Eight days post MPTP injections, serum was collected and used for mouse specific multi-analyte cytokine ELISA arrays. Cytokine
levels were determined from 4 to 6 animals per group ± SD (*p < 0.05 hCD34+ vs. C57BL/6; #p < 0.05 vs. hCD34+ mice, $p < 0.05 vs. C57BL/6)
Manocha et al. Molecular Neurodegeneration  (2017) 12:17 Page 13 of 18
validated as potential biomarkers for the disease, pos-
sibly in a sex selective fashion. In addition, it would be
very interesting to further study the direct effects of
these cytokines on brain changes in the humanized
CD34+ mice. Finally, unlike the C57BL/6 findings,
FK506 treatment had a dramatic effect on improving be-
havioral performance, increasing TH immunoreactivity,
decreasing microglial Iba-1 immunoreactivity, decreasing
GFAP astroglial immunoreactivity, and lowering serum
cytokine levels in the CD34+ humanized mice suggest-
ing potential for human translation. These data suggest
that the humanized immune system mice provide a
unique resource for characterizing the contribution of
inflammatory changes to disease.
Human CD34+ hematopoietic stem-cell engrafted
NSG mice develop multi-lineage human immune cells
and have become a popular, valid platform for infectious
disease research and cancer biology, especially with
respect to immune-oncology studies [36]. Engraftment
of human hematopoietic stem cells is much more effi-
cient in female scid mice as compared to males [37].
Therefore humanized CD34+ mice from Jackson La-
boratories can only be obtained as females. In this study,
age-matched female C57BL/6 mice were used for com-
paring differences between the human and mouse sys-
tems. Many murine MPTP-related studies are typically
performed on male mice to avoid the increased risk of
fatalities observed with females [38]. However, even
more surprising to us was the fact that the combined
MPTP + FK506 treatment group experienced higher
levels of toxicity in the C57BL/6 strain totaling near 50%
of animal loss in this group and not the MPTP or FK506
alone mice. In addition, with the limited numbers sur-
viving in this group there were no drug-dependent
apparent anti-inflammatory effects associated with re-
duction of cytokines in the serum or brains. The dose of
Fig. 11 MPTP injections increased levels of human inflammatory cytokines in the striatum of humanized CD34+ mice. The hCD34+ mice were
intraperitoneal injected three times with saline vehicle or MPTP-HCL (18 mg/kg) at 2 h intervals followed by FK506 injections (10 mg/kg/day) for
5 days. Eight days post MPTP injections, striatum were dissected out, lysed and used for human specific multi-analyte cytokine ELISA arrays. Cytokine
levels were determined from 6 animals per group ± SD (*p < 0.05)
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FK506 was chosen based on previously reported work
that demonstrated protection against MPTP-induced
dopamine depletion in the striatum of MPTP-injected
C57BL/6 mice using 10 mg/kg/day FK506 [39]. The lack
of protective effects of FK506 in MPTP-injected C57BL/
6 mice was surprising. One possible explanation for this
is that the MPTP injection paradigm is typically
performed in male mice and our study was necessarily
performed in female mice in order to be able to compare
to the female humanized CD34+ mice. The fact that
FK506 did not provide the benefits predicted may be
due to sex differences. However, we cannot rule out the
possibility that a different concentration of FK506 with-
out overt toxicity may have also provided benefits in the
female C57BL/6 mice. Due to limitations in the number
of available humanized CD34+ mice for the study de-
sign, alternative FK506 dosage interventions were not
possible. This increased toxicity susceptibility of C57BL/
6 female mice to the dosage of FK506 used is, in itself,
interesting and worth pursuing in future work. Under-
standing this vulnerability may give some insight into un-
derstanding the reason for drug-induced nephrotoxicity in
some patients. Although we can only hypothesize, we ex-
pect that the loss of TH immunoreactivity in the C57BL/6
mice is primarily due to the more classic model of direct
neurotoxicity by MPP+. Conversely, a significant portion
of the loss of TH immunoreactivity in the CD34+ human-
ized mice involves an inflammatory component that is
preventable by FK506 treatment.
Even though the specific changes in temporal pheno-
type of immune cells in both the brain and periphery
during PD remain unclear, it is well-known that either of
these cell types rely upon secretion of a number of cyto-
kines, such as IL-1β, IL-6 and TNF-α to act via both
Fig. 12 The striatums of humanized CD34+ and C57BL/6 mice displayed different murine cytokine levels after MPTP or FK506 injection. Humanized
CD34+ and C57BL/6 female mice were intraperitoneal injected three times with saline vehicle or MPTP-HCL (18 mg/kg) at 2 h intervals followed by
FK506 injections (10 mg/kg/day) for 5 days. Eight days post MPTP injections, striatum was dissected out, lysed and used for mouse specific multi-
analyte cytokine ELISA arrays. Cytokine levels were determined from 4 to 6 animals per group ± SD (*p < 0.05 hCD34+ vs. C57BL/6; #p < 0.05 vs. hCD34
+ mice, $p < 0.05 vs. C57BL/6 mice)
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paracrine and autocrine cellular mechanisms [15, 40]. In
an effort to identify particular brain cytokines that were
exclusive to the humanized immune system, we quanti-
fied an array of cytokines expression profiles in C57BL/6
mice vs. humanized CD34+ mice and serum cytokines
vs. brain cytokines. We also compared the plasma
cytokine profiles from human PD patients and healthy
controls to identify a few cytokines such as IL-1α, IL-2,
IL-4, and IL-6 as unique and robust serum biomarkers
of human disease that were replicated in the brains and
serum of the humanized CD34+ mice. This suggests
opportunity for further studies involving immunosup-
pressive therapeutic targets and even enticing possibil-
ities of small scale clinical trials using FK506 in order to
quantify changes in serum levels of these cytokines to
reflect an anti-inflammatory effect in the brain in correl-
ation with behavioral improvement in PD patients.
Since the humanized CD34+ mice have not been very
well characterized with regards to brain biology, it was
difficult to know beforehand whether or not there would
be any presence of human cells in the brains of 12 weeks
post-engrafted mice. However, immunostaining against
human specific macrophage antigens demonstrated the
presence of sparse meningeal-like human CD45 and
human HLA-DR specific immunoreactivity. The immu-
nostaining was clearly not as robust in the brain as com-
pared to the spleen and intestine, there is a possible role
of parenchymal brain microgliosis and cytokine secre-
tion in these mice. Nevertheless, we also cannot rule out
the possibility that increases in human specific cytokines
in both serum and brains of MPTP injected humanized
CD34+ mice and detection of human macrophage
markers such as CD68 and CD45 in peripheral organs
such as intestine and spleen suggests that the peripheral
Fig. 13 Human PD plasma had elevated levels of IL-1α, IL-2, IL-4 and IL-6 compared to healthy controls. Plasma from male and female Parkinson’s
disease donors and age-matched healthy controls was used to perform cytokine ELISAs. Mean values from 14 to 34 patients per condition were
averaged and graphed ± SD (*p < 0.05)
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immune system in these mice is effectively populated
with human immune cells and that the cytokines pro-
duced by these cells may be infiltrating the brain from
the periphery to perhaps drive the gliosis, behavioral def-
icits, and loss of TH staining. Indeed, recent work dem-
onstrates the presence of lymphatic vessels in the brain
that might allow for the cytokine or lymphocyte influx
[41]. It would be very exciting to repeat this work with
the humanized CD34+ mice and determine whether iv
delivery of select human cytokines that were elevated by
the MPTP treatment and in human PD plasma, IL-1α,
IL-2, IL-4, or IL-6, are sufficient to produce the brain
changes observed (i.e. gliosis, motor deficit, loss of TH
staining, and elevated brain cytokines). Conversely, se-
lective cytokine receptor antagonists or neutralizing
antibodies may be able to attenuate the adverse ef-
fects of MPTP injection in these mice. This may pro-
vide significant insight into understanding whether a
peripheral immune change can drive the brain disease
in humans. Overall, this study demonstrates for the
first time, the MPTP induced PD model in female
humanized CD34+ mice and a possible therapeutic
effect of FK506 in treating the MPTP-associated be-
havior deficits as well as inflammatory responses ob-
served during the disease.
Conclusions
These data demonstrate for the first time, induction of
Parkinson’s disease-like symptoms in female humanized
CD34+ mice using MPTP. There are distinct species dif-
ferences between the cytokine profiles of humanized
CD34+ mice and C57BL/6 mice. MPTP was able to pro-
duce loss of tyrosine hydroxylase immunoreactivity, loss
of motor strength, and increase in proinflammatory cy-
tokines in both strains of mice. However, these effects
were attenuated using an immunosuppressant drug,
FK506, only in the humanized CD34+ mice. Our data
suggest that these mice may represent a more accurate
model for assessing inflammatory changes in PD and
developing anti-inflammatory therapeutics.
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